Carteolol is a beta adrenergic antagonist used to treat arrhythmia, angina, hypertension, and glaucoma. A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
- Mechanism
- Curator reviewed
The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade.
- Primary indication
- For the treatment of intraocular hypertension and chronic open-angle glaucomaCurator reviewed · 4 structured indications
- Formula / weight
- C16H24N2O3 · 292.3734 g/mol (avg)
- First approval
- United States, 2000
- Brand names
Resolves to
Structure
InChIKey
LWAFSWPYPHEXKX-UHFFFAOYSA-NSMILESCC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2Targets
What you can answer from here — as of September 12, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Carteolol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account